Monday, May 31, 2021 – 13:45 | Last Update : 31 05 2021 – 13:45
TÜBİTAK President Hasan Mandal stated that it is planned to make the VLP-based domestic vaccine available as of November-December this year against the new type of coronavirus (Kovid-19) epidemic.
Reminding that they support 7 domestic vaccine studies on Kovid-19, Mandal noted that Phase-1 of the VLP-based vaccine has been completed.
Mandal stated that the final examinations of the results are being carried out and that they are planning to start Phase-2 work as of June 10.
Pointing out that the VLP vaccine is a very innovative type of vaccine in the world, Mandal stated that there are 4 research studies in this direction in the world, none of them has been used yet, and that it is critical that Turkey is the first to do this.
Mandal stated that their goal is to start Phase-3 from August and said, “Phase-2 study will work with both the original Wuhan virus and the British variant. I hope that in November-December, if everything goes as planned, if the emergency use permit is given, our country’s own We will have made the domestic and national vaccine usable, as VLP. We have two other vaccine candidates. One of them is an innovative inactivated vaccine candidate. He is about to complete Phase-1 studies. The other is in the phase of Phase-1 initiation.” said.
Mandal, co-founder of BioNTech Prof. Dr. Stating that they have been in contact with Uğur Şahin since April last year, he said:
“Our communication with him is not only about the pandemic period we have experienced. In fact, his field of competence is cancer vaccines. In this period, our country has experience and valuable teachers. Not only for Kovid-19, Turkey is no longer a country that imports vaccines in the future, but also develops and produces vaccines. Our goal is to make Turkey a central country in developing vaccines for different threats and different needs in the future. Within that scope, our future-oriented, research-based views continue with our teacher Uğur. “